Neuromodulators are in the news. I mean, no surprise there; they usually are, but this time, the conversation feels more medical than cosmetic. As of Tuesday, January 27, reports confirmed that 15 drugs, including Botox Cosmetic, were selected for the latest round of the Medicare Drug Price Negotiation Program.
Together, the drugs selected for this round of negotiations represent roughly $27 billion in total prescription drug spending, making them some of the most costliest medications covered by Medicare.
“For too long, seniors and taxpayers have paid the price for skyrocketing prescription drug costs,” said Centers for Medicare & Medicaid Services (CMS) administrator Dr. Mehmet Oz. “CMS is taking strong action to target the most expensive drugs in Medicare, negotiate fair prices and make sure the system works for patients—not special interests. This approach delivers real savings while strengthening accountability across the program.”
So what does that actually mean? It does not mean cheaper ‘tox appointments (sorry). Botox Cosmetic has long been covered by Medicare for approved medical uses, but this marks the first time Medicare is stepping in to negotiate its price, a move that could eventually lower costs for patients who rely on Botox for conditions such as chronic migraine, muscle spasticity or overactive bladder.
Drugmakers, including Botox Cosmetic’s manufacturer, have until the end of the month to decide whether to participate in negotiations. Opting out would mean removing the drug from Medicare entirely, a move most companies are unlikely to make. As reported by NBC News, “in the past two rounds of negotiations, no drugmakers opted out.”
In the meantime, patients can expect more clarity once companies make their decisions. NewBeauty will share updates as they become available.
